CTIS2023-505441-69-00进行中（未招募）1 期
INTEGRATE IIb A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - AG0315OG/CTC0140
Institut fuer Klinische Krebsforschung IKF GmbH0 个研究点目标入组 460 人开始时间: 2023年7月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Adults (18 years or over) with metastatic or locally recurrent gastro- oesophageal cancer which: a. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and b. is of adenocarcinoma or undifferentiated carcinoma histology; and c. is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrolment; and d. has failed or been intolerant to a minimum of 2 lines of prior anti- cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue. Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment. e.HER2-positive participants must have received trastuzumab, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1)., Ability to swallow oral medication., Adequate bone marrow function (Platelets =100x109/L; Absolute Neutrophil Count (ANC) =1.5x109/L and Haemoglobin = 9.0g/dL)., Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine =1.5 x Upper Limit of Normal (ULN)., Adequate liver function (Serum total bilirubin =1.5 x ULN, and INR = 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) =2.5 x ULN (= 5 x ULN for participants with liver metastases)). Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists., Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up., Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday), Signed, written informed consent.
排除标准
- •Known allergy to the investigational product drug class or excipients in the regorafenib and/or nivolumab, Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization, Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization., Venous thrombotic events and pulmonary embolism within 3 months prior to randomization, Any haemorrhage or bleeding event = Grade 3 according to CTCAE v5.0 within 4 weeks prior to randomization., Non-healing wound, ulcer, or bone fracture., Interstitial lung disease with ongoing signs and symptoms, Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed., Persistent proteinuria of = Grade 3 according to CTCAE v5.0 (equivalent to > 3.5g of protein over 24 hour measured on either a random specimen or 24 hour collection., Uncontrolled metastatic disease to the central nervous system. To be eligible, known CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time., History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study: a. curatively treated cervical carcinoma in situ, b. non-melanomatous carcinoma of the skin, c. superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]), d. treated thyroid papillary cancer, Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management)., Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy., Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrolment, Patients with a = grade 3 active infection according to CTCAE version 5.0, Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease who require pharmacotherapy. Low dose steroids (e.g. = 10 mg prednisone) are permitted, Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy; if used as replacement therapy e.g. = 10 mg prednisolone or dexamethasone = 2 mg per day) or immunosuppressants, or who have received such a therapy < 14 days prior to randomisation, Patients with a seizure disorder who require pharmacotherapy, Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol., Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal infertile, or use a reliable means of contraception. Women of childbearing potential (WOCBP) must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a ba
研究者
相似试验
进行中（未招募）
1 期
INTEGRATE IIb - A Randomised Phase III Open Label Study in which patients with advanced Stomach / oesophageal cancer who have failed prior therapy will be treated either with regorafenib and nivolumab or a standard chemotherapyEUCTR2020-004617-12-ATAustralasian Gastro-Intestinal Trials Group (AGITG)450
暂停
3 期
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Canceron-Small Cell Lung Cancernon-small cell lung cancerLBCTR2022055019ovartis Pharmaceuticals8
招募中
3 期
Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with non-small cell lung cancer.CTRI/2023/03/050253ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatmentPrimary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment.MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001671-21-PTKartos Therapeutics, Inc.385
进行中（未招募）
1 期
This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatmentEUCTR2018-001671-21-BGKartos Therapeutics, Inc.385